Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia (CCAP)

Clinical Trial ID NCT04345289

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04345289

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996 35.00
2 A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020 10.90
3 Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020 6.59
4 The acute respiratory distress syndrome. J Clin Invest 2012 5.61
5 Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med 2006 5.28
6 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 4.49
7 Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding. J Virol 1994 2.27
8 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020 2.03
9 The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2014 1.88
10 Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis 2011 1.68
11 Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J 2005 1.43
12 Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med 2017 1.39
13 The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2011 1.34
14 Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun 2004 1.31
15 Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res 2007 1.24
16 Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005 1.23
17 Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004 0.93
18 Immunoanatomic distribution of blood group antigens in the human urinary tract. Influence of secretor status. Lab Invest 1986 0.92
19 pH-dependent entry of chikungunya virus into Aedes albopictus cells. Infect Genet Evol 2012 0.83
20 Female donors and transfusion-related acute lung injury: A case-referent study from the International TRALI Unisex Research Group. Transfusion 2010 0.82
21 Extraordinary GU-rich single-strand RNA identified from SARS coronavirus contributes an excessive innate immune response. Microbes Infect 2012 0.81
22 ISBT 128: a global information standard. Cell Tissue Bank 2010 0.80
23 Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. J Rheumatol 1997 0.79
24 Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017 0.75
25 Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag 2019 0.75
Next 100